First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.
Status:
Completed
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
Based on conventional chemotherapy approach, data have indicated that the Folfirinox regimen
is more effective and tolerate than the treatment by Gemcitabine alone in patients with
metastatic pancreatic adenocarcinoma. A recent study combining gemcitabine and nab paclitaxel
improve the objective response rate.
Primary objective of this study is to identify the maximun tolerated dose and the recommended
phase II dose of first line treatment combining gemcitabine plus nab-paclitaxel followed by
folfirinox in metastatic pancreatic adenocarcinoma.